Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for emotion recognition in Alzheimer's disease and vascular dementia
ACTRN12617001531303Phase 4Terminated
- Sponsor
- University of Sydney
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxytocin in Alzheimer's disease (AD) and vascular dementia (2 arms), sponsored by University of Sydney. Primary endpoints: Ability to infer mental states, Perspective-taking and 1 more. Started Feb 2018; status: terminated.
02
Drugs
oxytocin
03
Conditions
Alzheimer's disease (AD)vascular dementia
Beyond the preview
Go deeper on ACTRN12617001531303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001531303.